compounded semaglutide hims Novo Nordisk calls out dangers of GLP-1s in new ad Affordability and Safety: How Hims

While data has been mainly retrospective, it has ranged from specific patient groups, such as those with hormone receptorpositive disease receiving endocrine therapy 1 or those only receiving semaglutide and tirzepatide with stage I to III breast cancer, 2 to patients from the broader breast cancer population receiving a range of GLP-1 agonists

Not intended for injection in humans or animals outside of controlled laboratory settings

This website does not provide medical advice and does not endorse or recommend any specific medications or treatment protocols

Emphasis is placed on mechanistic properties, signaling hypotheses, and system-level interaction

This new collection is available now at www.patchmd.com/glp-1-patches.html

Primary cutaneous synovial sarcoma: a case report